Search results
- To develop oral medication through the discovery of small molecule inhibitors of Sclerostin, a collaborative research agreement was signed by Zydus Lifesciences Ltd, Ahmedabad and Central Drug Research Institute, Lucknow. Under this agreement, CDRI and Zydus will jointly undertake preclinical research.
pib.gov.in/PressReleasePage.aspx?PRID=2060360
People also ask
Will CDRI & Zydus collaborate on preclinical research?
What is CDRI & Zydus Lifesciences Ltd?
What is a collaborative research agreement with sclerostin?
Will Zydus develop a drug for chronic kidney disease-induced osteoporosis?
4 days ago · A collaborative research agreement was inked between the parties to develop oral medication through the discovery of small molecule inhibitors of Sclerostin, the Ahmedabad-based drug firm said in a regulatory filing. As per the agreement, CDRI and Zydus will jointly undertake preclinical research, it said.
- Zydus ties up with CSIR-CDRI to develop drug for CKD-induced ...
A collaborative research agreement was inked between the...
- CDRI: CDRI Unveils Protein-Drug Combination to Combat ...
To develop oral medication through the discovery of small...
- Zydus ties up with CSIR-CDRI to develop drug for CKD-induced ...
2 days ago · To develop oral medication through the discovery of small molecule inhibitors of Sclerostin, a collaborative research agreement was signed by Zydus Lifesciences Ltd, Ahmedabad and Central Drug Research Institute, Lucknow. Under this agreement, CDRI and Zydus will jointly undertake preclinical research.
1 day ago · Ahmedabad: Zydus Lifesciences Ltd, Ahmedabad has signed a collaborative research agreement with Central Drug Research Institute, Lucknow for the development of best-in-class drug for Chronic Kidney Disease induced Osteoporosis. "To develop oral medication through the discovery of small molecule inhibitors of Sclerostin, a collaborative research ...
4 days ago · A collaborative research agreement was inked between the parties to develop oral medication through the discovery of small molecule inhibitors of Sclerostin, the Ahmedabad-based drug firm said in ...
1 day ago · With their combined strengths and shared vision, CDRI and Zydus are poised to set new standards in the treatment of bone metabolism disorders, ultimately improving health outcomes and quality of life for countless CKD patients.
2 days ago · To develop oral medication through the discovery of small molecule inhibitors of sclerostin, CDRI and Zydus Lifesciences Ltd, Ahmedabad, have signed a collaborative research agreement, under which ...
5 days ago · In a significant move to address chronic kidney disease (CKD) complications, Zydus Lifesciences has announced a collaborative research agreement with the Lucknow-based CSIR-Central Drug Research Institute (CDRI) to develop an innovative oral medication targeting chronic kidney disease-induced osteoporosis.
